Skip to main content

Research Repository

Advanced Search

All Outputs (237)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival (2020)
Journal Article
Joseph, C., Alsaleem, M., Orah, N., Narasimha, P. L., Miligy, I. M., Kurozumi, S., …Rakha, E. A. (2020). Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 182, 267–282. https://doi.org/10.1007/s10549-020-05670-x

Purpose: MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of... Read More about Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer (2020)
Journal Article
Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), https://doi.org/10.1186/s12885-020-06939-6

Background PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important pro... Read More about PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

A novel prognostic two-gene signature for triple negative breast cancer (2020)
Journal Article
Alsaleem, M. A., Ball, G., Toss, M. S., Raafat, S., Aleskandarany, M., Joseph, C., …Rakha, E. (2020). A novel prognostic two-gene signature for triple negative breast cancer. Modern Pathology, 33, 2208–2220. https://doi.org/10.1038/s41379-020-0563-7

The absence of a robust risk stratification tool for triple negative breast cancer (TNBC) underlies imprecise and non-selective treatment of these patients with cytotoxic chemotherapy. This study aimed to interrogate transcriptomes of TNBC resected s... Read More about A novel prognostic two-gene signature for triple negative breast cancer.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer (2020)
Journal Article
Ansari, R., Craze, M. L., Alfarsi, L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 181(1), 1-12. https://doi.org/10.1007/s10549-020-05586-6

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequenc... Read More about The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age (2020)
Journal Article
Johnston, S. J., Syed, B. M., Parks, R. M., Monteiro, C. J., Caruso, J. A., Green, A. R., …Cheung, K. L. (2020). Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age. Cancers, 12(3), Article 712. https://doi.org/10.3390/cancers12030712

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Multi-cohort analysis demonstrated that cytoplasmic cyclin E expression in primary breast tumors predicts aggressive disease. However, compared to their younger counterparts, older patients ha... Read More about Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age.

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers (2020)
Journal Article
Janssen, E. A., Ogden, A., Bhattarai, S., Sahoo, B., Mongan, N. P., Alsaleem, M., …Aneja, R. (2020). Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 10(1), Article 3009. https://doi.org/10.1038/s41598-020-59514-1

© 2020, The Author(s). Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) have been investigated as triple-negative breast cancer (TNBC) biomarkers. Reduced EGFR levels can be compensated by increases in HER3;... Read More about Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article
Alfarsi, L. H., El-Ansari, R., Craze, M. L., Masisi, B. K., Mohammed, O. J., Rakha, E. A., …Green, A. R. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 21(4), Article 1407. https://doi.org/10.3390/ijms21041407

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer (2019)
Journal Article
Ansari, R. E., Craze, M. L., Althobiti, M., Alfarsi, L., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. British Journal of Cancer, 122(1), 94–101. https://doi.org/10.1038/s41416-019-0626-z

Background: Cancer cells must alter their metabolism to support proliferation. Immune evasion also plays a role in supporting tumour progression. This study aimed to find whether enhanced glutamine uptake in breast cancer (BC) can derive the existenc... Read More about Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.

Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients (2019)
Journal Article
Mohammed, R. A. A., El-Deek, H. E. M., Aleskandarany, M. A., Green, A. R., Ellis, I. O., & Rakha, E. A. (2019). Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients. Egyptian Journal of Pathology, 16(1), 115-122. https://doi.org/10.4103/EGJP.EGJP_15_19

Background and aims: Clinicopathological features of Basal-like Breast Cancer (BLBC) in African American women have been extensively studied. Comparatively, less is known about these tumors in patients from countries in the North African region. The... Read More about Clinicopathological Characteristics of Basal-like Breast Cancer (BLBC): a Comparative Study between Egyptian and British Patients.

Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression (2019)
Journal Article
Kotecha, S., Lebot, M. N., Sukkarn, B., Ball, G., Moseley, P. M., Chan, S. Y., …Storr, S. J. (2019). Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. Scientific Reports, 9, 1-11. https://doi.org/10.1038/s41598-019-53529-z

Dopamine and cAMP regulated phosphoprotein 32?kDa (DARPP-32) also known as phosphoprotein phosphatase-1 regulatory subunit 1B and encoded by the PPP1R1B gene is an inhibitor of protein phosphatase-1 and protein kinase A. DARPP-32 is expressed in a wi... Read More about Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression.

The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer (2019)
Journal Article
Aljohani, A. I., Toss, M. S., Kurozumi, S., Joseph, C., Aleskandarany, M. A., Miligy, I. M., …Rakha, E. (2020). The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 179(1), 79–90. https://doi.org/10.1007/s10549-019-05459-7

Background: Lymphovascular invasion (LVI) is a prerequisite step in breast cancer (BC) metastasis. We have previously identified wild type isocitrate dehydrogenase 2 (IDH2) as a key putative driver of LVI. Thus, we explored the prognostic significanc... Read More about The prognostic significance of wild type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Dual Adaptive Pyramid Network for Cross-Stain Histopathology Image Segmentation (2019)
Book Chapter
Hou, X., Liu, J., Xu, B., Liu, B., Chen, X., Garibaldi, J., …Qiu, G. (2019). Dual Adaptive Pyramid Network for Cross-Stain Histopathology Image Segmentation. In Medical Image Computing and Computer Assisted Intervention – MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13–17, 2019, Proceedings, Part II (101-109). Springer Verlag. https://doi.org/10.1007/978-3-030-32245-8_12

Supervised semantic segmentation normally assumes the test data being in a similar data domain as the training data. However, in practice, the domain mismatch between the training and unseen data could lead to a significant performance drop. Obtainin... Read More about Dual Adaptive Pyramid Network for Cross-Stain Histopathology Image Segmentation.

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer (2019)
Journal Article
Joseph, C., Al-Izzi, S., Alsaleem, M., Kurozumi, S., Toss, M., Arshad, M., …Rakha, E. A. (2019). Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 121(9), 776-785. https://doi.org/10.1038/s41416-019-0589-0

© 2019, The Author(s), under exclusive licence to Cancer Research UK. Background: Retinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to explore the prognostic signi... Read More about Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer (2019)
Journal Article
Taylor, K. M., Green, A. R., Ellis, I. O., Gee, J. M. W., Ziliotto, S., Zilio, S., …Taylor, K. M. (2019). Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. Metallomics, 11(9), 1579-1592. https://doi.org/10.1039/c9mt00136k

ZIP7, a member of the ZIP family of zinc importers, resides on the endoplasmic reticulum membrane and transports zinc from intracellular stores to the cytoplasm after activation by CK2 phosphorylation on two serine residues (S275 and S276). ZIP7 is k... Read More about Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy (2019)
Journal Article
Alfarsi, L., Ansari, R. E., Craze, M. L., Toss, M. S., Masisi, B., Ellis, I. O., …Green, A. R. (2019). CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 178(3), 535-544. https://doi.org/10.1007/s10549-019-05420-8

Purpose Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and... Read More about CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ (2019)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Mittal, K., Green, A. R., Aneja, R., …Rakha, E. A. (2020). Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. Journal of Clinical Pathology, 73(2), 76-82. https://doi.org/10.1136/jclinpath-2019-205939

Aims: Cathepsin V (CTSV/CTSL2) is a lysosomal cystine proteinase and plays a role in extracellular matrix degradation. It is associated with poor prognosis in invasive breast cancer (IBC), but its role in breast ductal carcinoma in situ (DCIS) remain... Read More about Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.

Machine learning-based prediction of breast cancer growth rate in-vivo (2019)
Journal Article
Bhattarai, S., Klimov, S., Aleskandarany, M. A., Burrell, H., Wormall, A., Green, A. R., …Aneja, R. (2019). Machine learning-based prediction of breast cancer growth rate in-vivo. British Journal of Cancer, 121, 497–504. https://doi.org/10.1038/s41416-019-0539-x

Background Determining the rate of breast cancer (BC) growth in vivo, which can predict prognosis, has remained elusive despite its relevance for treatment, screening recommendations and medicolegal practice. We developed a model that predicts the r... Read More about Machine learning-based prediction of breast cancer growth rate in-vivo.

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk (2019)
Journal Article
Klimov, S., Miligy, I. M., Gertych, A., Jiang, Y., Toss, M. S., Rida, P., …Aneja, R. (2019). A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research, 21(1), Article 83. https://doi.org/10.1186/s13058-019-1165-5

© 2019 The Author(s). Background: Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from local recu... Read More about A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution (2019)
Journal Article
Miligy, I. M., Toss, M. S., Khout, H., Hc, B., Ellis, I. O., Green, A. R., …Rakha, E. (2019). Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 25(6), 1143-1153. https://doi.org/10.1111/tbj.13425

Background: Management of breast ductal carcinoma in situ (DCIS) has various approaches with distinct institutional specific practice. Here, we review DCIS management in a single institution with emphasise on re-operation rates and outcome. Methods:... Read More about Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution.